Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2423 | Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen Wiki | 1.00 |
drug2425 | Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen Wiki | 1.00 |
drug1904 | High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
drug1902 | High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen Wiki | 1.00 |
drug1906 | High-dose placebo (18-59 years) & Two dose regimen Wiki | 1.00 |
drug2426 | Low-dose placebo (18-59 years) & Three dose regimen Wiki | 1.00 |
drug2429 | Low-dose placebo (60-85 years) & Two dose regimen Wiki | 1.00 |
drug1908 | High-dose placebo (60-85 years) & Two dose regimen Wiki | 1.00 |
drug1901 | High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen Wiki | 1.00 |
drug1370 | Doxycycline Hcl Wiki | 1.00 |
drug1905 | High-dose placebo (18-59 years) & Three dose regimen Wiki | 1.00 |
drug2428 | Low-dose placebo (60-85 years) & Three dose regimen Wiki | 1.00 |
drug2422 | Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen Wiki | 1.00 |
drug2427 | Low-dose placebo (18-59 years) & Two dose regimen Wiki | 1.00 |
drug2424 | Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen Wiki | 1.00 |
drug1903 | High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen Wiki | 1.00 |
drug4694 | Vitamin D3 Wiki | 0.41 |
drug4781 | Zinc Wiki | 0.35 |
drug4690 | Vitamin C Wiki | 0.27 |
drug2230 | Ivermectin Wiki | 0.21 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.07 |
D007239 | Infection NIH | 0.05 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This is a phase Ⅱ, single-center, randomized, double-blind, placebo-controlled study, to evaluate the immunogenicity and safety of the recombinant COVID-19 vaccine (Sf9 cells) in the subjects from healthy adults and elderly adults aged 18 years and above (aged 18-60 and 60-85 years) with different immunization procedures (0, 21 days and 0, 14, 28 days) and doses (20μg/40μg).
Description: Geometric mean (GMT) of specific antibody against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike protein Receptor-binding domain(S-RBD) protein (ELISA)
Measure: Geometric mean (GMT) of specific antibody Time: 1 months after immunization in each study groupDescription: The incidence of adverse reaction (AR)
Measure: The incidence of adverse reaction (AR) Time: 0 to 7 days after vaccination in each study groupDescription: The incidence of adverse events (AE)
Measure: The incidence of adverse events (AE) Time: 0 to 28 days after vaccination in each study groupDescription: The incidence of severe adverse events (SAE)
Measure: The incidence of severe adverse events (SAE) Time: 0 to 28 days after vaccination in each study groupDescription: The incidence of serious adverse events
Measure: The incidence of serious adverse events Time: 6 months after vaccination in each study groupDescription: Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies (euvirus and pseudovirus-neutralizing assays)
Measure: Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies Time: 1 months after immunization in each study groupDescription: The positive conversion rate of S-RBD protein-specific antibody (ELISA) against SARS-CoV-2
Measure: The positive conversion rate of S-RBD protein-specific antibody Time: 14 days, 30 days after immunization in each study groupDescription: Geometric mean fold increase (GMI) of S-RBD protein-specific antibody (ELISA) against SARS-CoV-2
Measure: Geometric mean fold increase (GMI) of S-RBD protein-specific antibody Time: 14 days, 30 days after immunization in each study groupDescription: Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies (euvirus and pseudovirus-neutralizing assays)
Measure: Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies Time: 14 days after immunization in each study groupDescription: The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (euvirus and pseudovirus neutralization test)
Measure: The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody Time: 14 days, 30 days after immunization in each study groupDescription: Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodies (eucivirus and pseudovirus neutralization assays)
Measure: Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodies Time: 14 days, 30 days after immunization in each study groupDescription: The consistency analysis of the specific antibody (ELISA) and the specific neutralizing antibody (euvirus and pseudovirus neutralization assays) against SARS-CoV-2 S-RBD protein
Measure: The consistency analysis of the specific antibody and the specific neutralizing antibody Time: 1 months after immunization in each study groupDescription: The geometric mean titer (GMT) ratio of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody in each study groups
Measure: The geometric mean titer (GMT) ratio of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody Time: 1 months after immunization in each study groupDescription: The persistence (GMT,GMI,positive conversion rate) of specific antibodies against SARS-CoV-2 S-RBD protein
Measure: The persistence (GMT,GMI,positive conversion rate) of specific antibodies Time: 6 months after vaccination in each study groupDescription: Subtypes of IgG antibodies against the S-RBD protein of SARS-CoV-2 after immunization in each study group
Measure: Subtypes of immunoglobulin G (IgG) antibodies Time: 1 months after immunization in each study groupAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports